Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03698162 · ClinicalTrials.gov registry record · NA
Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases
A NA study, sponsored by University of Southern California.
- Terminated
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT03698162 is a NA study that was terminated before completion, run by University of Southern California. The registered enrollment target is 15 participants.
The verdict
NCT03698162, a NA study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
Dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) is a potentially powerful diagnostic tool for the management of brain cancer and other conditions in which the blood-brain barrier is compromised. This trial studies how well precise DCE MRI works in diagnosing participants with high grade glioma that has come back or melanoma that has spread to the brain. The specially-tailored acquisition and reconstruction (STAR) DCE MRI could provide improved assessment of brain tumor status and response to therapy.
Interventions
- OTHER Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- OTHER Bevacizumab Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-04-13 |
| Est. Completion | 2025-03-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03698162
The ClinicalTrials.gov registry entry for NCT03698162 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dynamic Contrast-Enhanced Magnetic Resonance Imaging is the first listed.
NCT03698162 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03698162 about?
NCT03698162 is a clinical study titled "Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases". Dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) is a potentially powerful diagnostic tool for the management of brain cancer and other conditions in which the blood-brain barrier is compromised. This trial studies how well precise DCE MRI works in diagnosing participants with high g...
What is the current status of trial NCT03698162?
This trial is currently terminated. It is a NA study. The enrollment target is 15 participants. The study started on 2021-04-13. Estimated completion is 2025-03-01.
What interventions are being tested in trial NCT03698162?
The interventions under investigation include: Dynamic Contrast-Enhanced Magnetic Resonance Imaging (OTHER), Bevacizumab Injection (OTHER).
Who is sponsoring clinical trial NCT03698162?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.